NCT02971891View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

PHASE3CompletedINTERVENTIONAL

Enrollment

484

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

April 16, 2018

Study Completion Date

July 10, 2018

Conditions

Cutaneous Common Warts

Interventions

DRUG

CLS006 (Furosemide) Topical Gel

DRUG

Vehicle Topical Gel

Trial Locations (30)

10022

New York

18201

Hazleton

19034

Fort Washington

21030

Hunt Valley

24501

Lynchburg

27262

High Point

28405

Wilmington

32174

Ormond Beach

33137

Miami

33162

North Miami Beach

33624

Tampa

36608

Mobile

46168

Plainfield

68144

Omaha

70605

Lake Charles

71203

Monroe

77494

Katy

77845

College Station

78213

San Antonio

78229

San Antonio

78759

Austin

80220

Denver

84117

Salt Lake City

85308

Glendale

90045

Los Angeles

90404

Santa Monica

95403

Santa Rosa

480059

Fort Gratiot

01915

Beverly

03801

Portsmouth

All Listed Sponsors

lead

Maruho Co., Ltd.

INDUSTRY

NCT02971891 - A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts | Biotech Hunter | Biotech Hunter